Period:
Draw Mode:
| Volume | 69,949 |
|
|||||
| News | (2) | ||||||
| Day High | 10.86 | Low High |
|||||
| Day Low | 10.16 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Celcuity Inc | CELC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.155 | 1.5% | 10.51 | 11:51:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 10.31 | 10.16 | 10.86 | 10.355 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,327 | 69,949 | $ 10.50 | $ 734,693 | - | 4.81 - 14.402 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:51:11 | 52 | $ 10.51 | USD |
Celcuity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 227.96M | 21.69M | 17.31M | $ - | $ - | -2.64 | -4.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 177.79k | 20.30% |
Celcuity News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.97 | 11.00 | 9.12 | 10.25 | 106,267 | 0.54 | 5.42% |
| 1 Month | 11.59 | 11.855 | 9.12 | 10.50 | 103,875 | -1.08 | -9.32% |
| 3 Months | 10.82 | 12.58 | 9.08 | 10.65 | 65,664 | -0.31 | -2.87% |
| 6 Months | 9.43 | 14.402 | 7.50 | 10.71 | 47,040 | 1.08 | 11.45% |
| 1 Year | 8.70 | 14.402 | 4.81 | 9.16 | 61,587 | 1.81 | 20.8% |
| 3 Years | 6.50 | 33.01 | 4.03 | 17.67 | 76,573 | 4.01 | 61.69% |
| 5 Years | 16.43 | 33.01 | 4.03 | 17.85 | 51,118 | -5.92 | -36.03% |
Celcuity Description
| Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR). |